![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Proceeds from the financing will be used to advance Asalyxa Bio's lead development candidate, ASX-100, into first-in-human clinical trials.
Lead Product(s): Salicylic Acid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Bridge Partners
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 23, 2021
Details:
ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.
Lead Product(s): ASX-100
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orange Grove Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 25, 2020